GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhongyuan Union Cell & Gene Engineering Corp Ltd (SHSE:600645) » Definitions » ROC %

Zhongyuan Union Cell & Gene Engineering (SHSE:600645) ROC % : 4.74% (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Zhongyuan Union Cell & Gene Engineering ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Zhongyuan Union Cell & Gene Engineering's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was 4.74%.

As of today (2025-04-01), Zhongyuan Union Cell & Gene Engineering's WACC % is 11.64%. Zhongyuan Union Cell & Gene Engineering's ROC % is 3.35% (calculated using TTM income statement data). Zhongyuan Union Cell & Gene Engineering earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Zhongyuan Union Cell & Gene Engineering ROC % Historical Data

The historical data trend for Zhongyuan Union Cell & Gene Engineering's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongyuan Union Cell & Gene Engineering ROC % Chart

Zhongyuan Union Cell & Gene Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.30 4.23 3.13 2.81 3.23

Zhongyuan Union Cell & Gene Engineering Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.58 0.14 4.13 4.39 4.74

Zhongyuan Union Cell & Gene Engineering ROC % Calculation

Zhongyuan Union Cell & Gene Engineering's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=179.995 * ( 1 - 25.67% )/( (4163.925 + 4123.098)/ 2 )
=133.7902835/4143.5115
=3.23 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5284.619 - 282.16 - ( 1393.432 - max(0, 1471.495 - 2310.029+1393.432))
=4163.925

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5411.355 - 261.494 - ( 1581.245 - max(0, 1481.737 - 2508.5+1581.245))
=4123.098

Zhongyuan Union Cell & Gene Engineering's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=260.336 * ( 1 - 25.65% )/( (4100.427 + 4062.573)/ 2 )
=193.559816/4081.5
=4.74 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5309.097 - 231.134 - ( 1453.409 - max(0, 1467.657 - 2445.193+1453.409))
=4100.427

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5280.484 - 245.321 - ( 1438.429 - max(0, 1481.844 - 2454.434+1438.429))
=4062.573

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhongyuan Union Cell & Gene Engineering  (SHSE:600645) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Zhongyuan Union Cell & Gene Engineering's WACC % is 11.64%. Zhongyuan Union Cell & Gene Engineering's ROC % is 3.35% (calculated using TTM income statement data). Zhongyuan Union Cell & Gene Engineering earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Zhongyuan Union Cell & Gene Engineering ROC % Related Terms

Thank you for viewing the detailed overview of Zhongyuan Union Cell & Gene Engineering's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhongyuan Union Cell & Gene Engineering Business Description

Traded in Other Exchanges
N/A
Address
45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
Executives
Li De Fu Director
Wang Xue Jun senior management
Wang Yong Director
Li Hai Bin Director
He Wei senior management
Li Qiang senior management
Wu Ming Yuan Director
Wang Hui Director
Huang Jia Xue senior management
Cao Hai Feng Director
Han Yue E Director
Liu Yong Jun senior management
Cui Jing Xue Supervisors
Yang Guang Xing senior management
Meng Zhi Hong senior management

Zhongyuan Union Cell & Gene Engineering Headlines

No Headlines